Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback